
    
      This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed
      to evaluate the efficacy and safety of a 5-day regimen of favipiravir in influenza patients
      aged 20-80 years. Enrolled patients will be randomly assigned to 1 of 3 parallel treatment
      dose groups:Placebo; Low-dose favipiravir (1000 mg favipiravir BID for 1 day, followed by 400
      mg favipiravir BID for 4 days); High-dose favipiravir (1200 mg favipiravir BID for 1 day,
      followed by 800 mg favipiravir BID for 4 days).
    
  